Capital Markets

• eHi Car Services in its US$325 million Regulation S high-yield bond offering due 2027
• CICC as the sole sponsor and overall coordinator in the approximately US$31 million IPO of Qyuns Therapeutics Co., Ltd. (2509.HK) on the Hong Kong Stock Exchange
• OrbusNeich Medical Group (6929.HK) in its US$62 million IPO and listing on the Hong Kong Stock Exchange
• 3D Medicines Inc. (1244.HK) in its US$52 million IPO and listing on the Hong Kong Stock Exchange
• Gushengtang Holdings Limited (2273.HK) in its US$104 million IPO and listing on the Hong Kong Stock Exchange
• Keymed Biosciences Inc. (2162.HK) in its US$398 million IPO and listing on the Hong Kong Stock Exchange
• Hua Medicine (2552.HK) in its US$110 million IPO and listing on the Hong Kong Stock Exchange
• ABCI Captial Limited, CICC Hong Kong Securities Limited and other underwriters in the H-share IPO of Lushang Life Services Co., Ltd (2376.HK) on the Hong Kong Stock Exchange
• China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$133 million IPO of mobile game publisher FingerTango Inc.(6860.HK) on the Hong Kong Stock Exchange
• China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$40 million IPO of mobile game publisher Digital Hollywood Interactive Limited (2022.HK) on the Hong Kong Stock Exchange
• Pharmaron (3759.HK) in its Regulation S private offering of US$600 million of zero coupon convertible bonds due 2026
• eHi Car Services (NYSE: EHIC) in its Regulation S private offering of US$400 million Senior Unsecured Notes

Mergers and Acquisitions

• Pacific Alliance Group (PAG) in its US$756 Million acquisition of three office towers in China and its subsequent disposal of its investment portfolio
• TTM Technologies, Inc. (NASDAQ: TTMI) in its US$660 million sale of substantially all of its China-based mobility business to Chinese consortium AKMMeadville Electronics (Xiamen) Co., Ltd.
• eHi Car Services (NYSE: EHIC) in its US$937.5 million going private transaction
• the three founders of Nanjing USA, Inc. in their trade sale to Roo Hsing Co., Ltd., a Taiwan listed company
• Nissan (China) Investment Co., Ltd. in its acquisitions of a majority stake of a China-based insurance brokerage company and a China-based financing leasing company
• Warner Brothers in its exit from China joint ventures
• Targus Cayman HoldCo Limited in its sale valued at approximately US$250 million
• a Shenzhen Stock Exchange listed company in its acquisition of a U.S.-based medical device manufacturer
• a Shenzhen Stock Exchange listed sport manufacture company in its proposed acquisition of a U.S.-based sport and entertainment company
• a U.S. energy company in its divestment from its joint venture in China
• a U.S. medical equipment manufacturer in its sales of 100% of its equity to a Chinese bidder

Private Equity/Venture Capital

• a leading Shanghai-based IDC service provider in its Series A/pre-IPO financings
• Hua Medicine in its US$117 million Series D and Series E financings
• a leading Suzhou-based antibody therapeutics company in its Series C and C+ financing
• a leading Hangzhou-based cloud computing and big data service provider in its Series B financing
• a leading Zhuhai-based monoclonal antibody drugs biotech in its US$150 million Series A financing
• Autohome Inc. (NASDAQ: ATHM) in its US$100 million convertible bonds investment in a leading Chinese online vehicle sales company
• a leading Asian venture investment fund in its exchangeable bonds investment in a Chinese energy group
• a Shanghai-based state-owned investment management company in its PIPE investment in an NYSE-listed U.S. high-tech manufacture company
• a leading Chinese information technology services provider listed on the Shenzhen Stock Exchange in its investment in a U.K.-based leading telematics company
• a leading China-based genomic company in its investment in and licensing technology from a U.K.-based genomic analytics company
• a Chinese listed medical company in its proposed investment in a NASDAQ-listed Israel clinical-stage biotherapy company
• a Hong Kong Stock Exchange listed holding company in its PIPE investment in an NYSE-listed leading theme park and entertainment company
• a U.S.-based industrial group in its investment in an NYSE-listed Chinese e-commerce company
• various venture capital deals including representations of internationally recognized venture capital funds and start-up or pre-IPO companies

Joint Ventures, Foreign Direct Investment and General Corporate

• Accuray (NASDAQ: ARAY) in its formation of a joint venture with China Isotope and Radiation Corporation to manufacture and sell radiation oncology systems in China
• a U.K.-based alternative energy technology company in its establishment of a joint venture enterprise with its Chinese partner in China
• a U.S. sheet music publisher on its China development and cooperation strategies
• several foreign non-profit organization on their establishment and operation in China
• general corporate matters of multinational companies' subsidiaries and rep offices in China